SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) — Clene, Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical.
An internationally recognized expert in treating disorders of the central nervous system, Dr. Greenberg brings extensive clinical and research experience to Clene as the company continues its development of CNM-Au8® as a potential treatment for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
“Dr. Greenberg’s depth of experience will be invaluable to us as we advance the Phase 3 clinical development programs for CNM-Au8 in ALS and MS, especially as Ben has already been advising Clene for many years and is extremely familiar with CNM-Au8 and its data,” said, Rob Etherington, Clene’s CEO. “We are committed to help make neurodegenerative diseases treatable and believe that his contributions across our therapeutic areas of focus will be important. Robert Glanzman, MD FAAN, Clene’s current Chief Medical Officer will continue to serve the Company in an advisory role. We thank Dr. Glanzman for his work in advancing our lead asset to late-stage clinical development. We are well-positioned to continue disclosing additional data from our programs and will work to progress our discussions with potential pharma partners and regulatory agencies.”
Dr. Greenberg joins Clene alongside his current role as professor of neurology and Vice Chair of Clinical and Translational Research in the Department of Neurology at UT Southwestern Medical Center in Dallas, TX. His clinical and research expertise spans many areas of neurology including the diagnosis and treatment of MS and other rare neurological disorders.
Dr. Greenberg received his Bachelor’s degree from Johns Hopkins University and his Master’s degree in Molecular Microbiology and Immunology from the Johns Hopkins School of Public Health. He graduated from Baylor College of Medicine and completed an internal medicine internship at Rush Presbyterian-St. Luke’s Medical Center in Chicago, before going on to residency in neurology at The Johns Hopkins Hospital in Baltimore.
“I am excited to join the incredible team at Clene to support the development of CNM-Au8,” said Benjamin Greenberg, M.D. “Despite recent advances in neurotherapeutics there is a critical unmet need for effective and safe treatments that slow or prevent neurodegeneration. The potential of CNM-Au8 to treat neuronal dysfunction broadly is an important scientific advancement for people living with these diseases, as its mechanism of action may be widely applicable to many neurodegenerative disorders. I look forward to advancing the CNM-Au8 neurodegenerative clinical program for disorders such as ALS and MS.”
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc.
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Clene’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include our ability to demonstrate the efficacy and safety of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
|Media Contact |
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
- Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Credit Suisse Group AG (CS) - March 23, 2023
- Unity Care Receives $100,000 California State Coastal Conservancy Grant - March 23, 2023
- Maui Land & Pineapple Company, Inc. Reports Fiscal 2022 Results - March 23, 2023